Trillium Therapeutics presented interim data from its ongoing Phase 1 trial of the SIRPaFc TTI-621 at ASH this past weekend. These highly anticipated results gave a deeper look into the.
ASH has more or less come and gone. This is usually a highly anticipated conference that has some game changing data. While this was once again highly anticipated, I have.
We are in a lull before a flood of data arrives at the end of this week and then into ASH next week. There is not a lot of new.
I vaguely (not really vaguely) recall noting last Tuesday that we were likely done with news unless some company wanted to sneak bad news in right before the holiday. I.
An exciting return to the sector for me and I mean that sarcastically. Not really much to talk about heading into this Thanksgiving week and I would not be surprised.
Again we do not have a ton of news but we had one of our first year end catalysts, which I will talk about. In terms of the year end.
And we continue with the Trump effect in the sector. As I noted before this is going to be a longer term tailwind despite what people argue about the potential.
On October 9, 2016, I made a prediction about this election that has come true. Hillary would lead the polls by 5 points throughout the election, and Trump would win..
This is going to be a very interesting test for the sector. There are two events that should crush the sector (or would have recently) but will it? Odds are.
Sarepta Therapeutics, Inc. (SRPT) -Nasdaq During the past six weeks we had so many stories, with or against SRPT approval, where a 10-million shares short sellers are still traped in.
There has been nothing reasonable, rational, or predictable about the price action in the sector recently. The sell off yesterday on the ASH abstracts (supposedly the catalyst) is the height.
Any selling we see today cannot really be blamed on sentiment or the elections as we had our first day (in my opinion) of fundamentally bad earnings. Up to this.
There is nothing that seems to help the sector. The clear sentiment headwind is the election and that is certainly plausible. A non-democratic sweep of the presidency, senate, and house.
It looks like the sector is not responding well to decent news. As I noted yesterday nothing has had a perfect press release but given the selloff perfect news was.
We have almost a perfect storm of negativity to hit the sector to start the week- a week that people were already worried about with the slew of earnings that.
Clearly the sector did not turn the corner after the presidential debate even though it should have assuaged concerns over the importance of drug pricing to the candidates. The sector.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
It is still not great out there for the sector but yesterday was not awful, which I guess is an improvement. Perhaps we have reached a short term bottom and.
Financial markets talk about a lot of headwinds to the economy. China devaluation, negative S&P earnings, presidential race, central bank actions, European banking problems, Japan, oil, etc. One that should.